🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Pfizer Gains Premarket on FDA’s Nod to Covid-19 Booster for Higher-Risk Groups

Published 09/23/2021, 04:50 AM
Updated 09/23/2021, 04:55 AM
© Reuters.
PFE
-

By Dhirendra Tripathi

Investing.com – Pfizer stock (NYSE:PFE) traded 1% higher in Thursday’s premarket following the Food and Drug Administration’s approval of booster shots of its Covid-19 vaccine for people at higher risk of infection.

This means that people 65 years and older and vulnerable individuals at risk of catching the illness will be able to get a third shot of the Pfizer-BioNTech mRNA vaccine. The two companies developed the vaccine jointly and share the revenue from the vaccine sales equally.

Patients should receive a booster at least six months after taking the second dose, the FDA said.

The need for a booster dose after studies indicated the efficacy of the two-dose vaccine declined after a certain period and that a third dose will help. The Delta variant of the original coronavirus that led to a resurgence of the pandemic in the U.S. and in other parts of the world this year was largely responsible for convincing the authorities of the need for a booster.

The Biden administration wanted a blanket approval for the booster to cover all adults but FDA advisors and experts advised against it.

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.